1. Home
  2. FRAF vs ALXO Comparison

FRAF vs ALXO Comparison

Compare FRAF & ALXO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Franklin Financial Services Corporation

FRAF

Franklin Financial Services Corporation

HOLD

Current Price

$58.45

Market Cap

255.8M

Sector

Finance

ML Signal

HOLD

Logo ALX Oncology Holdings Inc.

ALXO

ALX Oncology Holdings Inc.

HOLD

Current Price

$2.08

Market Cap

240.8M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
FRAF
ALXO
Founded
1906
2015
Country
United States
United States
Employees
N/A
N/A
Industry
Major Banks
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
255.8M
240.8M
IPO Year
1995
2020

Fundamental Metrics

Financial Performance
Metric
FRAF
ALXO
Price
$58.45
$2.08
Analyst Decision
Strong Buy
Analyst Count
0
4
Target Price
N/A
$3.50
AVG Volume (30 Days)
29.7K
1.2M
Earning Date
04-23-2026
05-08-2026
Dividend Yield
2.46%
N/A
EPS Growth
88.84
26.36
EPS
4.74
N/A
Revenue
N/A
N/A
Revenue This Year
$14.44
N/A
Revenue Next Year
$6.95
N/A
P/E Ratio
$12.14
N/A
Revenue Growth
N/A
N/A
52 Week Low
$33.44
$0.41
52 Week High
$60.00
$2.66

Technical Indicators

Market Signals
Indicator
FRAF
ALXO
Relative Strength Index (RSI) 60.25 60.00
Support Level $45.02 $1.99
Resistance Level $60.00 $2.30
Average True Range (ATR) 1.90 0.16
MACD -0.08 0.06
Stochastic Oscillator 69.98 95.76

Price Performance

Historical Comparison
FRAF
ALXO

About FRAF Franklin Financial Services Corporation

Franklin Financial Services Corp is a bank holding company based in the United States. It is engaged in general commercial, retail banking, and trust services normally associated with community banks. It offers a broad range of banking services to businesses, individuals, and governmental entities, which include accepting and maintaining cheques, savings, and time deposit accounts, providing investment and trust services, making loans and providing safe deposit facilities. The bank also performs personal, corporate, pension and fiduciary services through its Investment and Trust Services Department.

About ALXO ALX Oncology Holdings Inc.

ALX Oncology Holdings Inc is a clinical-stage immuno-oncology company focused on helping patients fight cancer by developing a pipeline of product candidates based on expertise in protein engineering and oncology led by the CD47 blocker, evorpacept, currently in phase 1 and 2 clinical trials. Cancer cells leverage CD47, a cell surface protein, as a don't eat me signal to evade detection by the immune system. It is developing a next-generation checkpoint inhibitor designed to have a high affinity for CD47 and to avoid the limitations caused by hematologic toxicities inherent in other CD47 blocking approaches.

Share on Social Networks: